What is Genprex?
Genprex is dedicated to pioneering life-changing gene therapies for patients battling cancer and diabetes. The company's innovative technologies aim to deliver disease-fighting genes, offering new therapeutic avenues for large patient populations with limited existing treatment options. Genprex collaborates with leading institutions to advance its pipeline of gene therapies, seeking to provide novel treatments.
How much funding has Genprex raised?
Genprex has raised a total of $33M across 2 funding rounds:
Stock Offering
$25.5M
Share Placement
$7.5M
Stock Issuance/Offering (2020): $25.5M, investors not publicly disclosed
Share Placement (2023): $7.5M, investors not publicly disclosed
What's next for Genprex?
The recent major strategic investment signals a pivotal phase for Genprex, likely enabling accelerated clinical development and pipeline expansion. This enterprise-level funding is expected to bolster research and development efforts, potentially paving the way for broader clinical trials and strategic partnerships. The company's focus on addressing significant unmet needs in oncology and endocrinology positions it for substantial growth and impact in the biotechnology sector.
See full Genprex company page
